We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Proteome Sciences Plc | LSE:PRM | London | Ordinary Share | GB0003104196 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.65 | 2.30 | 3.00 | - | 0.00 | 13:55:29 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 5.03M | -2.44M | -0.0083 | -3.19 | 7.82M |
Date | Subject | Author | Discuss |
---|---|---|---|
01/5/2024 07:15 | Presumably the other secondary avatar wasjobber is being prepped to verify that to be the case as we 'speak'? | barry evans | |
01/5/2024 06:30 | I'm not sure investors fully appreciate the significance of Proteome Sciences new 32-plex TMTpro reagents, which will probably be officially announced by Thermo at this years ASMS in Anaheim early next month. It's not just a near doubling of the current 18-plex TMTpro reagent, but also a massive improvement of Thermo's mass spec capabilities, which will leave their competitors far behind them in performance and sample throughput. One users perspective :- www.proteomicsnews.b The new 32-plex TMTpro reagents will have big consequences for the mass spec proteomics market and its competitors. | pools2 | |
28/4/2024 16:18 | Thermo Fisher Scientific Reports First Quarter 2024 Results24th April 24Source: Business WireThermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 30, 2024.First Quarter 2024 HighlightsFirst quarter revenue was $10.34 billion.First quarter GAAP diluted earnings per share (EPS) increased 4% to $3.46.First quarter adjusted EPS increased 2% to $5.11. | goggin | |
26/4/2024 20:41 | 10p-ish...Ha! i suspect that gave The Diggles, the giggles. ~40Mln buyout after 30 years-ish.......The mind boggles. | cdlaney | |
26/4/2024 17:24 | Well done PRM. Not a holder but wish them well | mashman | |
26/4/2024 10:37 | Oh look, more AZ pTau217 FDA designated blood tests, theyre like buses except prm dont have one 5:10 PM · Apr 18, 2024 Quanterix @QuanterixSimoa Exciting news in Alzheimer's care! Quanterix's Simoa® p-Tau 217 blood test has earned Breakthrough Device designation from the US FDA as a diagnostic aid for #Alzheimers. This pivotal moment in AD research offers new hope for #diagnosis and treatment. 3:22 PM · Apr 24, 2024 ADxHealth @adxhealth WellMind p-Tau217 is a blood test used to detect levels of Tau217, which has been shown to be elevated in Alzheimer's Disease patients and increase of the course of the disease. Launching Soon! | elpirata | |
26/4/2024 10:37 | Not on the radar- yet, needs 2 - 3 more wins | goggin | |
26/4/2024 10:28 | 3k of shares bought,tells you all you need to know. | peverill | |
26/4/2024 09:20 | It looks like Proteome Sciences share price is turning to an uptrend. The eight month downtrend has just been broken to the upside. Richard Dennis hints at further big contracts to come this year. Of course, this is all peanuts compared to the Alzheimer's disease, cancer and stroke IP that will lead to a significantly increased share price. STRONG BUY | wasjobber | |
26/4/2024 08:29 | Yes agreed, they have been a basket case but have survived. As many said, I don't know how they screwed up during covid but here we are. Where's there's life, anything is possible, just look at Trump | goggin | |
26/4/2024 08:24 | #92901 Noted with thanks Goggin. They are approaching 30 years in to that 2 year plan. | monte1 | |
26/4/2024 08:23 | Hugh Trees ? I can’t say that I know the fellow. | monte1 | |
26/4/2024 08:17 | America is a big market, this is hugely significant in terms regarding Proteome in a very competitive field plus as well as a major boust to company morally, they can tout this success with other players. Smal acorns can grow into Hugh trees. This is only a start but I would expect tgat if they can follow up with successful wins in the bext 6 month and develop a track record, then they will be taken over by one of the big boys as this is pocket change to them, probably 10p ish but it's a 2 year plan | goggin | |
26/4/2024 07:58 | WHH you are here long enough to know the score,it's flannel that will have no affect on the price.Its minuscule in the markets they work in and didn't need an RNS.The company is having our pants down yet again.Exorbitant wages for what they have delivered to shareholders for 30 years. | peverill | |
26/4/2024 07:36 | Peverill you fail to see the significance of this deal, it's not so much the value although this is significant in the context of last years results but an important first contract in America using our facilities' there and indicates that the move into America looks like it was justified and I believe that more contracts will emerge to augment this deal. Well done PRM. Hutch | wellhonedhutch | |
26/4/2024 07:12 | FFs,you wouldn't even RNS it.30 years in business and this is the best they can come up with,shameful,probab | peverill | |
26/4/2024 07:04 | And so it begins :o)) | wellhonedhutch | |
26/4/2024 06:52 | Oh my, how embarrassing. Announcing that, seriously? A £500k deal that 'a good proportion' will be in this financial year with an unnamed customer. This is chicken feed by any measure. | barry evans | |
26/4/2024 06:44 | We’ll done PRM. Helping the journey to revenue restoration!! Still hoping for 6p by Y/E. W41 | wrighty41 | |
26/4/2024 06:37 | A win for 500k, good start | goggin | |
24/4/2024 12:50 | When are this shower planning on giving shareholders a ROI.???? | peverill | |
22/4/2024 13:38 | #92891 Pictures? | dominiccummings | |
22/4/2024 12:48 | Lovely tight spread (:- | goggin | |
22/4/2024 09:17 | Is that why the share price has risen Barry? | dominiccummings |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions